Inogen will release its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. The medical technology company, specializing in respiratory products for homecare settings, will host a conference call the same day to discuss its performance. Investors and analysts can access the live webcast through the Inogen Investor Relations website, where the recording will be archived for six months.

Conference Call Details

The conference call is scheduled for August 6, 2026, at 2:00 p.m. PT / 5:00 p.m. ET. Participants can join via phone or webcast. A replay will be available approximately three hours after the live event and remain accessible until August 13, 2026.

Regulatory Disclosure

Inogen uses its Investor Relations website, http://investor.inogen.com/ , as a primary channel for disclosing material non-public information. This approach ensures compliance with its disclosure obligations under Regulation FD. The company continues to leverage digital platforms to maintain transparency with stakeholders.

About Inogen

Inogen is a global medical technology company focused on developing, manufacturing, and marketing respiratory therapy devices. Its products are designed to support patients with chronic respiratory conditions in homecare settings. The company collaborates with prescribers, home medical equipment providers, and distributors to ensure broad availability of its therapies.

Inogen, Inc. has appointed Andy Reding to the newly created role of Chief Operating Officer, effective July 6, 2026, to strengthen its leadership structure and support global commercial and operational execution. The medical technology company, listed on Nasdaq under the ticker INGN, aims to streamline operations as it diversifies through new product launches and geographic expansion. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and ensuring the company's strategy translates into efficient outcomes.

Executive Background

Andy Reding joins Inogen with more than 30 years of leadership experience across medical technology, commercial operations, product development, and healthcare reimbursement. Most recently, he served as Chief Commercial Officer of Viant Medical for over six years, leading teams across 25 facilities that support complex medical-device design and manufacturing programs. His tenure at Viant was marked by exceptional growth and support for hundreds of medical device companies globally.

Prior to his role at Viant Medical, Reding was Vice President and General Manager of Hillrom Respiratory Health. In this capacity, he led sales, marketing, customer service, research and development, reimbursement, and third-party billing. His team expanded the sales force, developed new products, and navigated FDA and CMS requirements to bring innovative products to market. Reding holds a Master of Business Administration from the University of South Carolina and a bachelor’s degree from Marquette University.

Strategic Appointment

Kevin Smith, Chief Executive Officer of Inogen, stated that the new appointment is designed to enhance execution and accelerate the delivery of strategic priorities. Smith highlighted Reding’s deep experience in building high-performing teams and scaling complex medical technology businesses as critical for driving top-line growth, advancing profitability, and expanding the innovation pipeline. Reding expressed his commitment to transforming Inogen into a global respiratory care leader by leveraging the company's strong foundation and mission.

Compensation Details

In connection with his employment, Andy Reding received an inducement equity award consisting of restricted stock units (RSUs) covering an aggregate of 130,000 shares of Inogen’s common stock. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4). Subject to Reding’s continued service with the company, one-third of the RSUs will vest annually over a period of three years.